Skip to main content
Clinical Trials/JPRN-UMIN000031451
JPRN-UMIN000031451
Completed
Phase 4

Study for the effect on blood pressure and heart rate fluctuation by switching from DPP-4 inhibitor to SGLT2 inhibitor Luseogliflozin in patients with type 2 diabetes. - multicenter, prospective, randomized, open-label, parallel group, comparison study - - Luseogliflozin ABPM study

Hokkaido University Hospital0 sites68 target enrollmentFebruary 28, 2018

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Type 2 diabetes mellitus
Sponsor
Hokkaido University Hospital
Enrollment
68
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 28, 2018
End Date
March 31, 2021
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Patients with taking SGLT2 inhibitors. 2\) Hypersensitivity to Luseogliflozin. 3\) Uncontrolled diabetic retinopathy 4\) Severe liver dysfunction, renal dysfunction, or heart failure 5\) Pregnancy, nursing woman or possibly pregnant woman 6\) Severe diabetic ketosis, diabetic coma 7\) Severe infection, pre and post operation , severe trauma 8\) Deficiency of insulin secretion 9\) BMI \< 22kg/m2 10\) eGFR \< 30 ml/min 11\) Patients with uncontrolled diet therapy. 12\) Patients with irregular circadian rhythm. 13\) Patients who thought to be inappropriate to enter this study for some reasons by physician's judgments

Outcomes

Primary Outcomes

Not specified

Similar Trials